Scientists close in on vaccine for stomach flu
TOKYO — As a new strain of stomach flu leaves a trail of stomach-clenching illness from Sydney to San Diego, scientists are moving closer to thwarting it for good.
Early-stage human studies on a vaccine against norovirus, the top source of gastroenteritis in the United States, are set to finish this year. A course of shots may confer lifelong protection against 95 percent of strains, said Rajeev Venkayya, who heads Japan's Takeda Pharmaceutical Co.'s vaccines unit.
A norovirus vaccine would be a boon to cruise ships, schools and nursing homes struggling to deal with a highly contagious, untreatable scourge. Of the 21 million people infected in the United States annually, about 800 die, mostly the very young and the elderly, according to the Centers for Disease Control and Prevention.
“Given the highly infectious nature of norovirus and its ability to cause extensive outbreaks in hospitals, elder-care facilities and cruise ships, there is a need for prophylactic and preventative approaches to guard against infection,” said Peter White, a microbiology professor at the University of New South Wales in Australia.
Norovirus can be caught from an infected person, contaminated food or water, or by touching contaminated surfaces, according to the CDC.
If approved, Takeda Pharmaceutical Co.'s norovirus vaccine would be the first to protect people against the germ.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Greece’s EU role hangs in limbo as voters reject bailout in referendum
- U.S.-led coalition unleashes wave of airstrikes on Raqqa, Syria
- Gene therapy for cystic fibrosis promising, study shows
- Wildfires break out in Spain, Portugal
- Iran nuclear deal teeters on ‘hard choices,’ Kerry says
- Egypt claims to kill 63 terrorists in North Sinai
- Pope comes ‘home’ to South America to defend planet and the poor
- Fans cheer as Princess Charlotte christened on British royal estate in Sandringham
- Militants attack Egyptian army checkpoints in Sinai, kill 53
- Egypt foiled extremist ‘state’ in Sinai, president says
- Draft accords of sanctions relief at Iran nuclear talks in hand